Huntington's Disease Therapeutics Market to Grow Owing to Introduction Of Innovative Drugs: Radiant Insights, Inc.

Monday, May 14, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

SAN FRANCISCO, May 14, 2018 /PRNewswire/ --

Global huntington's disease therapeutics market

is anticipated to grow at a steady CAGR in future. Hungtington's disease (HD) is mainly prevalent in adults which is chronic and progressively neurodegenerative disease by nature. Medically, it is characterized by choreic involuntary movements followed
by psychiatric, psychological and intellectual disorders and mainly characterized radiologically by striatal atrophy of varying degree. Genetically, Huntington's disease is an autosomal - dominantly inherited type of disease. HD can be looked upon as a model neurodegenerative disorder. Determination of biomarkers which reliably sense subtle changes of disease progression in order to be able to precisely assess the effects of disease modifying therapeutics.

Certain biomarkers comprising cognitive, clinical, behavioral neuro-imaging and neurophysiological phase need to be assessed during the detection of premotor phase. HD diseases result in certain motor impairments and thus neurophysiological assessment of central nervous system that need potential evaluation. Prevalence of hungtington's disease is common in adult age group from 30-40 years and patients beyond 40 or 50 are even diagnosed with some extra medications. Hence, it is likely that the ratio of late recipients of HD may get highlighted owing to aging population. Commercial market driving factors responsible for the growth of hungtington's disease include unmet medical needs, rise in pharmaceuticals and inception of innovative drugs. However, stringent regulations by government coupled with minimal approval for drugs hampers the market growth in the estimated period.

Geographically, the Huntington's disease therapeutics market spans North America, Latin America, Europe, Middle-East, Asia-Pacific and Africa. North America dominated the global market owing to rising cases of the disease and therapy for the same. Europe and MEA regions however witnessed a steady CAGR growth. APAC regions also exhibited a steady CAGR growth rate in the estimated period owing to rising cases of Huntington's disease.

Access 116 page research report with TOC on "Huntington's Disease Therapeutics Market" available with Radiant Insights, Inc. @

The key players in the hungtington's diseases therapeutics market include Valeant Pharmaceuticals International Inc., Alnylam Pharmaceuticals Inc., AmpliPhi Biosciences Corp, Ceregene Inc., Lundbeck, Prana Biotechnology Limited, Teva Pharmaceutical Industries Ltd., Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Auspex Pharmaceuticals, SOM Biotech, GlaxoSmithKline, Siena Biotech, Raptor Pharmaceutical, Pfizer, Palobiofarma, Omeros and Ipsen.

This report studies Huntington's Disease Therapeutics in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering 

•    Auspex Pharmaceuticals

•    Alnylam Pharmaceuticals

•    Intellect Neurosciences Incorporation

•    Lundbeck A/S

•    Prana Biotechnology Limited

•    Raptor Pharmaceuticals

•    Sangamo Biosciences

•    Teva Pharmaceutical Industries

•    Trophos SA

•    Valeant Pharmaceuticals International

•    Vertex Pharmaceuticals

Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Huntington's Disease Therapeutics in these regions, from 2011 to 2021 (forecast), like 

•    North America

•    Europe

•    China

•    Japan

•    Southeast Asia

•    India

Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into 

•    Type I

•    Type II

•    Type III

Split by application, this report focuses on consumption, market share and growth rate of Huntington's Disease Therapeutics in each application, can be divided into 

•    Application 1

•    Application 2

•    Application 3

Browse reports of similar category available with Radiant Insights, Inc.: 

  • EMEA Narcolepsy Therapeutics Industry
  • EMEA Molecular Microbiology Industry
  • EMEA Medical Marijuana Industry
  • EMEA Medical Guide Wire Industry

About Radiant Insights, Inc.: 

At Radiant Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.

Contact: Michelle Thoras. Corporate Sales Specialist Radiant Insights, Inc. Phone: +1-415-349-0054 Toll Free: 1-888-928-9744 Email:


SOURCE Radiant Insights, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store